Molagri Announces $5.8M for Precision Biopesticides

A honeybee has already helped shape the pest-control technology taking form at Molagri. The Toronto biotechnology startup says it mapped a honeybee receptor to understand how its engineered particles could avoid beneficial insects, bringing a pollinator into the design process before a grower ever buys the product.

That work now has more early capital behind it. Molagri announced $5.8M in combined pre-seed and seed funding on October 14, 2026, with Convective Capital leading the seed. Cofounders Zaky Hassan, CEO, and Min Jin, CSO, are developing precision biopesticides that could be adjusted as insects develop resistance, starting with pests affecting tree nuts and tree fruits.

The financing supports scientific recruitment and research at an expanded Toronto laboratory. For growers and crop-protection suppliers, the interesting proposition is a continuing relationship with the biology: a product whose targeting or insecticidal payload could change when the pest does, provided the science, manufacturing and review process can carry those changes into practical use.

What the $5.8M funds

Molagri's announcement names Y Combinator, Superorganism, Robinhood Ventures, Paul Graham and other angels alongside seed lead Convective Capital. Julian Capital was its earliest backer and led the pre-seed. The $5.8M figure combines both stages; Molagri did not separately disclose the incremental seed amount or a valuation.

That distinction keeps the financing attached to the actual development story. In a September interview with BetaKit, Hassan described $1M in pre-seed backing from Julian Capital and Y Combinator, which helped secure laboratory space and an early scientific hire. The previously reported money belongs inside the newly announced cumulative total.

The company has since expanded into laboratory space with biomanufacturing and tissue-culture facilities and says it filed a provisional patent covering its targeted delivery system. Those investments give a small scientific team more capacity to investigate a difficult combination of questions. A particle has to recognize the intended insect, reach the right cells, deliver its cargo and remain useful through the production process.

Molagri's spending priorities follow that sequence of work. Funding a team across the disciplines lets failures become something the scientists can diagnose together, rather than leaving each specialist to optimize an isolated piece of the eventual product.

Two parts that can change with the insect

Molagri develops engineered, non-infectious virus-like particles, or VLPs, as biological delivery vehicles. In the company's description, a targeting component recognizes receptors in a pest's gut, allowing genetic instructions to enter cells and cause them to produce an insecticidal payload. The intended selectivity comes from matching delivery to the target and choosing the payload carefully.

The founders' background makes the choice of delivery vehicle understandable. Hassan and Jin worked together on human coronaviruses as University of Toronto PhD lab mates before bringing their structural-biology and protein-biochemistry training into agriculture. Y Combinator's company profile identifies Molagri as a 2026 company from its Summer 2026 batch and describes the founders' work on the structures that govern biological recognition.

Modularity is central to the commercial idea. A change in an insect's receptor could require a different targeting element; resistance to a particular payload could call for a different way of killing the pest. Molagri aims to make those components replaceable while retaining a useful underlying delivery architecture.

DevCuration's Robigo coverage documents a separate engineered-biological approach within crop protection. Molagri's particle-delivery design would give its own business an ongoing research obligation. The supplier would need to understand which biological change explains declining performance and which adjustment deserves development. For an orchard operator, the value would arrive through a dependable product and a credible response when protection weakens. Molecular flexibility becomes commercially useful only as the supplier turns it into something the grower can use.

The work visible in the hiring plan

The current Molagri careers page lists four Toronto openings spanning synthetic virology and RNA delivery, insect biology and bioassays, yeast expression and VLP production, and molecular display and binder discovery. Together, the roles show how much of the company's next phase happens at the laboratory bench. They also identify the interfaces where a promising particle can fail.

The virology role includes packaging RNA, checking delivery and measuring payload expression. The insect-biology role covers cell and whole-insect assays, including dose response and species selectivity. Production work includes yield, purification and storage conditions, while binder discovery addresses recognition of insect receptors.

For a grower, those internal details eventually appear as simpler questions about dose, consistency and handling. A batch that performs differently after storage could change the usefulness of an otherwise promising biological design. Molagri's hiring plan connects the target-recognition story to the practical work of making material that can be tested repeatedly.

The company describes fermentation as its intended manufacturing route, with yeast production specifically reflected in the open role. Current job descriptions are evidence of the work being built, rather than proof of commercial manufacturing economics. The distinction leaves the scientific opportunity intact while showing where the funding is meant to go.

From an interested grower to a usable product

Molagri reports an initial grower letter of intent, giving the team an early commercial conversation around its science. In Elaine Watson's AgFunderNews interview, Hassan also acknowledges that field performance, manufacturing costs, formulation stability and commercial selectivity remain to be established. Licensing to established crop-protection businesses is among the options being considered.

A licensing route could put Molagri's research alongside an established supplier's commercial relationships. It would also make the evidence package central to that partnership: a prospective partner needs to understand what the particle does, how reliably it can be produced and what remains to be demonstrated. The present financing supports building that understanding.

The update ambition carries a further question about review. Hassan says Molagri is exploring how modifications might be assessed without every change losing the speed the modular design is intended to provide. The company has not established a settled regulatory route for those updates.

For now, tree nuts and tree fruits keep the development effort attached to particular growers and pests. As the Toronto team hires, each experiment can bring the response to resistance closer to a product decision: which target to pursue, which formulation to advance and which evidence a grower or commercial partner will need before putting it into a crop-protection program.